Cambrex Co. (CBM) Shares Sold by Wells Fargo & Company MN

Wells Fargo & Company MN cut its stake in Cambrex Co. (NYSE:CBM) by 73.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 296,494 shares of the biotechnology company’s stock after selling 830,093 shares during the quarter. Wells Fargo & Company MN owned 0.90% of Cambrex worth $16,307,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. YorkBridge Wealth Partners LLC grew its stake in shares of Cambrex by 5.2% in the second quarter. YorkBridge Wealth Partners LLC now owns 1,971 shares of the biotechnology company’s stock worth $118,000 after acquiring an additional 97 shares during the period. Riverhead Capital Management LLC boosted its holdings in shares of Cambrex by 90.3% in the second quarter. Riverhead Capital Management LLC now owns 2,664 shares of the biotechnology company’s stock worth $159,000 after buying an additional 1,264 shares during the last quarter. Advisor Group Inc. boosted its holdings in shares of Cambrex by 29.8% in the second quarter. Advisor Group Inc. now owns 2,681 shares of the biotechnology company’s stock worth $160,000 after buying an additional 615 shares during the last quarter. Flinton Capital Management LLC boosted its holdings in shares of Cambrex by 90.9% in the second quarter. Flinton Capital Management LLC now owns 3,570 shares of the biotechnology company’s stock worth $213,000 after buying an additional 1,700 shares during the last quarter. Finally, Trexquant Investment LP purchased a new position in shares of Cambrex in the third quarter worth approximately $209,000.

A number of equities analysts recently issued reports on CBM shares. BidaskClub downgraded shares of Cambrex from a “hold” rating to a “sell” rating in a report on Thursday, August 24th. Craig Hallum reissued a “buy” rating and issued a $60.00 price objective (down previously from $70.00) on shares of Cambrex in a report on Tuesday, October 31st. Finally, ValuEngine downgraded shares of Cambrex from a “buy” rating to a “hold” rating in a report on Friday, September 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $62.33.

Cambrex Co. (NYSE CBM) opened at $51.00 on Thursday. Cambrex Co. has a 1-year low of $42.55 and a 1-year high of $62.95. The firm has a market cap of $1,689.68, a P/E ratio of 16.26, a price-to-earnings-growth ratio of 1.16 and a beta of 2.26.

Cambrex (NYSE:CBM) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.08. Cambrex had a net margin of 18.79% and a return on equity of 23.42%. The business had revenue of $112.60 million for the quarter, compared to the consensus estimate of $108.44 million. During the same quarter in the previous year, the firm earned $0.47 earnings per share. The company’s revenue for the quarter was up 13.4% on a year-over-year basis. analysts predict that Cambrex Co. will post 2.97 earnings per share for the current fiscal year.

In other Cambrex news, CEO Steven M. Klosk sold 4,000 shares of Cambrex stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $54.96, for a total transaction of $219,840.00. Following the transaction, the chief executive officer now owns 87,328 shares of the company’s stock, valued at $4,799,546.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.48% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: This article was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.com-unik.info/2017/12/21/cambrex-co-cbm-shares-sold-by-wells-fargo-company-mn.html.

About Cambrex

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).

Institutional Ownership by Quarter for Cambrex (NYSE:CBM)

What are top analysts saying about Cambrex? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cambrex and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit